Our Mission

To improve the lives of those suffering from the debilitating effects of degenerative diseases of the spine.


Our Commitment

We are revolutionizing the way millions of patients suffering from chronic back pain will be treated. 

Our Focus

We are focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine.

Our Approach

We are engineering highly specialized therapeutic progenitor cells (Discogenic Cells) that uniquely address the complex environment of the degenerated disc. 


IDCT: A Regenerative Solution

DiscGenics’ first product candidate, IDCT, is an allogeneic (donor-derived), injectable (non-surgical) cell therapy that utilizes proprietary Discogenic Cells to treat degenerative disc disease.

We’ve seen a lot of new technologies come into the spine market in the last 25 years, but none are potentially as game changing as IDCT.
— Matthew F. Gornet, M.D., Orthopedic Surgeon

Featured News


Disclaimer: IDCT is an investigational product that is under development by DiscGenics and has not been approved by the U.S. Food & Drug Administration (FDA) or any other regulatory agency for human use.